Key points are not available for this paper at this time.
The synthesis and characterization of novel hetrometallic complexes cis ‐PtCl (NH 3) 2 (μ ‐4, 4′‐bipyridyl) ZnCl (terpy‐Cl) (ClO 4) 2 (C1a), trans ‐PtCl (NH 3) 2 (μ ‐4, 4′‐bipyridyl) ZnCl (terpy) (ClO 4) 2 (C2a), cis ‐PtCl (NH 3) 2 (μ ‐pyrazine) ZnCl (terpy‐Cl) (ClO 4) 2 (C3a) and trans ‐PtCl (NH 3) 2 (μ ‐pyrazine) ZnCl (terpy‐Cl) (ClO 4) 2 (C4a) (where terpy‐Cl = 4′‐chloro‐2, 2′: 6′, 2′′‐terpyridine) was done. Acid–base titrations were performed by UV–Vis spectrophotometric method to evaluate the p K a values of corresponding aqua complexes. Interactions between complexes and important biomolecules, guanosine‐5′‐monophosphate (5′‐GMP) and glutathione (GSH) were examined by 1 H NMR spectroscopy. The chloride substituent at the 4′ position on the middle pyridine ring of terpyridine ligand significantly affects the coordination of biomolecules, as well as overall stability of complexes. The complexes were evaluated in vitro for the antioxidant prevention of DNA damages. All tested novel complexes demonstrated a significant reduction in DNA damage against oxidative modifications of DNA caused by the hydroxyl and peroxyl radicals. Also, cytotoxicity evaluation showed that significant cytotoxicity occurs only after long‐term effect of C1a, C2a and C3a, complexes in HCT‐116 cells. Molecular docking studies predict results in agreement with experimental research.
Serezlić et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: